Presentation Title

Addressing CMV in Solid Organ Transplant Patients with CMV inSIGHT T Cell Immunity: Candid Case Studies

Guiding Difficult Treatment Decisions for Transplant Recipients

The use of CMV T Cell Immunity Panel to Assess the Risk of Clinically Significant CMV Infection in Recipients of Cellular Therapy with Low Level CMV Viremia

Gain inSIGHT into an Immunocompromised Patient's T Cell Immune Response featuring: CMV and SARS-CoV-2

Brief Synopsis

These unique case studies will cover situations like neutropenia, low-level CMV, the importance of CD4 T Cells and more. Learn when they use CMV inSIGHT T Cell Immunity testing to evaluate CMV-specific cell mediated immunity, what they do with the information from the lab report, and the outcomes of their patients.

During this excerpt of the panel discussion, speakers present case studies of their utilization of diagnostics to improve patient outcomes in challenging and complicated contexts. They will discuss practical uses of the inSIGHT™ t cell immunity assay, including their application in managing post-transplant patient care.

See how Dr. Chemaly and his team at MD Anderson have utilized CMV inSIGHT™ T Cell Immunity testing to identify cellular therapy recipients (both on and off letermovir for prophylaxis) who are high risk for clinically significant CMV infection. As well as, assess the benefit of early treatment of low level CMV viremia who are not on letermovir prophylaxis and high risk for clinically significant CMV infection. Determine the utility of the CMV inSIGHT™ T Cell Immunity test in the management of low level CMV viremia in high and low risk patient populations on letermovir.

Join Dr.'s Raval, Khawaja and Kleiboeker to learn more about virus-specific T cell mediated immunity for CMV and SARS-CoV-2. Dr. Raval, a board-certified Cardiologist, will share his experience utilizing the CMV T Cell Immunity panel in heart transplant patients. Dr. Khawaja, an Infectious Disease Physician, will present his experience with CMV cellular immunity in hematopoietic cell transplant recipients with low level viremia. Finally, Dr. Kleiboeker will describe the new SARS-CoV-2 inSIGHT T Cell Immunity test as well as discuss future T Cell Immunity testing innovations to come.

Length of Presentation

1 hour

15 minutes

24 minutes

47 minutes

Kidney

X

X

Liver

X

X

Heart

X

X

Lung

X

X

Hematopoietic Stem Cell Transplantation/Bone Marrow Transplantation

X

X

Infectious Disease

X

X

X

X